Skip to main content
. Author manuscript; available in PMC: 2021 Aug 19.
Published in final edited form as: J Invest Dermatol. 2019 Aug 15;140(2):435–444.e4. doi: 10.1016/j.jid.2019.06.146

Figure 4. Human IL17RA L-SNA reduces psoriatic cytokine production by keratinocytes in 3D organotypic rafts.

Figure 4.

3D models were treated with L-SNAs or PBS every other day starting 7 days after lifting. The cytokine mix was added 9 days after lifting, concurrent with L-SNAs (Suppl. Fig. 3d) and harvested on day 13. (a, b) Knockdown of IL17RA was determined by qRT-PCR and western blotting. Dose-dependent knockdown of psoriasis-associated genes by IL17RA L-SNAs (vs. controls) in 3D rafts: (c) PI3, (d) DEFB4, (e) IL17C, and (f) TNFA. (g) LOR, which is reduced in psoriasis, is partially rescued by IL17RA SNA treatment. Values reported as mean ± standard error of the mean. * P < 0.05, ** P < 0.01, *** P < 0.001. 3D, 3-dimensional; IL17RA L-SNA, IL-17A receptor liposomal spherical nucleic acid; L-SNA, liposomal spherical nucleic acid; n.s, not significant; PBS, phosphate buffered saline; qRT-PCR, quantitative real-time reverse transcriptase–PCR; Scr L-SNA, scrambled liposomal spherical nucleic acid; TNF-α, tumor necrosis factor α.